 Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and efficacy questions that had at least one analyst lower his sales forecast. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
